Human pancreatic RNase1-human epidermal growth factor fusion

An entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas

Kyriakos Psarras, Masakazu Ueda, Tadashi Yamamura, Soji Ozawa, Masaki Kitajima, Sadakazu Aiso, Setsuko Komatsu, Masaharu Seno

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The gene encoding human pancreatic ribonuclease 1 (hpRNase1) was fused with a gene encoding human epidermal growth factor (hEGF). The hybrid human protein was isolated from Escherichia coli inclusion bodies, refolded and purified to homogeneity. The fusion protein competed with 125I-hEGF for binding to hEGF receptors (EGFR) and had ribonucleolytic activities approaching those of hpRNase1. Several conformations having different enzymatic activities could be detected after reversed-phase high-performance liquid chromatographic analysis, the less hydrophobic molecules being the most active. The hybrid protein was specifically cytotoxic to A431, an EGFR overexpressing squamous carcinoma cell line, with an IC50 of ~10-7 M. In contrast, recombinant hpRNase1 had an IC50 higher than 10-4 M. A mixture of free hEGF and free hpRNase1 was not more cytotoxic than hpRNase1 alone and no cytotoxicity was detected in EGFR-deficient control cells. Taken together, these data suggest that this construct might be useful for targeted therapy of esophageal, lung and other squamous cell carcinomas and also breast cancers overexpressing EGFR, which correlate with a poor prognosis and cannot be cured by surgery alone. Engineering hybrid molecules with endogenous human proteins for targeted therapy may alleviate the dose-limiting immunogenicity and toxicity of conventional immunotoxins.

Original languageEnglish
Pages (from-to)1285-1292
Number of pages8
JournalProtein Engineering
Volume11
Issue number12
Publication statusPublished - Dec 1998

Fingerprint

Immunotoxins
Pancreatic Ribonuclease
Epidermal Growth Factor
Squamous Cell Carcinoma
Fusion reactions
Proteins
Gene encoding
Molecules
High performance liquid chromatography
Cytotoxicity
Surgery
Escherichia coli
Toxicity
Conformations
Inhibitory Concentration 50
Epithelial Cells
Ribonucleases
Inclusion Bodies
Reverse-Phase Chromatography
Genes

Keywords

  • EGF receptor
  • Fusion protein
  • Human pancreatic RNase1
  • Immunotoxin analog
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Human pancreatic RNase1-human epidermal growth factor fusion : An entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. / Psarras, Kyriakos; Ueda, Masakazu; Yamamura, Tadashi; Ozawa, Soji; Kitajima, Masaki; Aiso, Sadakazu; Komatsu, Setsuko; Seno, Masaharu.

In: Protein Engineering, Vol. 11, No. 12, 12.1998, p. 1285-1292.

Research output: Contribution to journalArticle

Psarras, Kyriakos ; Ueda, Masakazu ; Yamamura, Tadashi ; Ozawa, Soji ; Kitajima, Masaki ; Aiso, Sadakazu ; Komatsu, Setsuko ; Seno, Masaharu. / Human pancreatic RNase1-human epidermal growth factor fusion : An entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. In: Protein Engineering. 1998 ; Vol. 11, No. 12. pp. 1285-1292.
@article{e8cb78c4486b4d7b98a8b8377352cd11,
title = "Human pancreatic RNase1-human epidermal growth factor fusion: An entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas",
abstract = "The gene encoding human pancreatic ribonuclease 1 (hpRNase1) was fused with a gene encoding human epidermal growth factor (hEGF). The hybrid human protein was isolated from Escherichia coli inclusion bodies, refolded and purified to homogeneity. The fusion protein competed with 125I-hEGF for binding to hEGF receptors (EGFR) and had ribonucleolytic activities approaching those of hpRNase1. Several conformations having different enzymatic activities could be detected after reversed-phase high-performance liquid chromatographic analysis, the less hydrophobic molecules being the most active. The hybrid protein was specifically cytotoxic to A431, an EGFR overexpressing squamous carcinoma cell line, with an IC50 of ~10-7 M. In contrast, recombinant hpRNase1 had an IC50 higher than 10-4 M. A mixture of free hEGF and free hpRNase1 was not more cytotoxic than hpRNase1 alone and no cytotoxicity was detected in EGFR-deficient control cells. Taken together, these data suggest that this construct might be useful for targeted therapy of esophageal, lung and other squamous cell carcinomas and also breast cancers overexpressing EGFR, which correlate with a poor prognosis and cannot be cured by surgery alone. Engineering hybrid molecules with endogenous human proteins for targeted therapy may alleviate the dose-limiting immunogenicity and toxicity of conventional immunotoxins.",
keywords = "EGF receptor, Fusion protein, Human pancreatic RNase1, Immunotoxin analog, Targeted therapy",
author = "Kyriakos Psarras and Masakazu Ueda and Tadashi Yamamura and Soji Ozawa and Masaki Kitajima and Sadakazu Aiso and Setsuko Komatsu and Masaharu Seno",
year = "1998",
month = "12",
language = "English",
volume = "11",
pages = "1285--1292",
journal = "Protein Engineering, Design and Selection",
issn = "1741-0126",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Human pancreatic RNase1-human epidermal growth factor fusion

T2 - An entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas

AU - Psarras, Kyriakos

AU - Ueda, Masakazu

AU - Yamamura, Tadashi

AU - Ozawa, Soji

AU - Kitajima, Masaki

AU - Aiso, Sadakazu

AU - Komatsu, Setsuko

AU - Seno, Masaharu

PY - 1998/12

Y1 - 1998/12

N2 - The gene encoding human pancreatic ribonuclease 1 (hpRNase1) was fused with a gene encoding human epidermal growth factor (hEGF). The hybrid human protein was isolated from Escherichia coli inclusion bodies, refolded and purified to homogeneity. The fusion protein competed with 125I-hEGF for binding to hEGF receptors (EGFR) and had ribonucleolytic activities approaching those of hpRNase1. Several conformations having different enzymatic activities could be detected after reversed-phase high-performance liquid chromatographic analysis, the less hydrophobic molecules being the most active. The hybrid protein was specifically cytotoxic to A431, an EGFR overexpressing squamous carcinoma cell line, with an IC50 of ~10-7 M. In contrast, recombinant hpRNase1 had an IC50 higher than 10-4 M. A mixture of free hEGF and free hpRNase1 was not more cytotoxic than hpRNase1 alone and no cytotoxicity was detected in EGFR-deficient control cells. Taken together, these data suggest that this construct might be useful for targeted therapy of esophageal, lung and other squamous cell carcinomas and also breast cancers overexpressing EGFR, which correlate with a poor prognosis and cannot be cured by surgery alone. Engineering hybrid molecules with endogenous human proteins for targeted therapy may alleviate the dose-limiting immunogenicity and toxicity of conventional immunotoxins.

AB - The gene encoding human pancreatic ribonuclease 1 (hpRNase1) was fused with a gene encoding human epidermal growth factor (hEGF). The hybrid human protein was isolated from Escherichia coli inclusion bodies, refolded and purified to homogeneity. The fusion protein competed with 125I-hEGF for binding to hEGF receptors (EGFR) and had ribonucleolytic activities approaching those of hpRNase1. Several conformations having different enzymatic activities could be detected after reversed-phase high-performance liquid chromatographic analysis, the less hydrophobic molecules being the most active. The hybrid protein was specifically cytotoxic to A431, an EGFR overexpressing squamous carcinoma cell line, with an IC50 of ~10-7 M. In contrast, recombinant hpRNase1 had an IC50 higher than 10-4 M. A mixture of free hEGF and free hpRNase1 was not more cytotoxic than hpRNase1 alone and no cytotoxicity was detected in EGFR-deficient control cells. Taken together, these data suggest that this construct might be useful for targeted therapy of esophageal, lung and other squamous cell carcinomas and also breast cancers overexpressing EGFR, which correlate with a poor prognosis and cannot be cured by surgery alone. Engineering hybrid molecules with endogenous human proteins for targeted therapy may alleviate the dose-limiting immunogenicity and toxicity of conventional immunotoxins.

KW - EGF receptor

KW - Fusion protein

KW - Human pancreatic RNase1

KW - Immunotoxin analog

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=0032423372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032423372&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1285

EP - 1292

JO - Protein Engineering, Design and Selection

JF - Protein Engineering, Design and Selection

SN - 1741-0126

IS - 12

ER -